Nebulized bimosiamose – anti-inflammatory pan-selectin antagonist for the treatment of COPD

D. Bock, A. Wenker, B. Müllinger, D. Beyer, K. Schierhorn, W. Meyer-Sabellek (Hennigsdorf, Gemünden/Wohra, Germany)

Source: Annual Congress 2009 - Treatment of airways disease
Session: Treatment of airways disease
Session type: Thematic Poster Session
Number: 2092
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Bock, A. Wenker, B. Müllinger, D. Beyer, K. Schierhorn, W. Meyer-Sabellek (Hennigsdorf, Gemünden/Wohra, Germany). Nebulized bimosiamose – anti-inflammatory pan-selectin antagonist for the treatment of COPD. Eur Respir J 2009; 34: Suppl. 53, 2092

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014


Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 613s
Year: 2007

PF-00610355 – an inhaled β2 adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009

Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs
Source: Annual Congress 2011 - Understanding disease and drug mechanisms
Year: 2011


The in-vitro pharmacology of PF-3429281 – A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010

First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 35s
Year: 2001

β2 long-acting and anticholinergic drugs synergistically control TGFβ1-mediated neutrophilic inflammation in COPD: An "in vitro" model
Source: Annual Congress 2011 - COPD: clinical studies and animal cell models
Year: 2011


Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study},
Source: Eur Respir J 2012; 40: 830-836
Year: 2012



Leukotriene receptor antagonist (LTRA) montelukast for the treatment of acute bronchiolitis in infants
Source: Eur Respir J 2004; 24: Suppl. 48, 504s
Year: 2004

First line anti-inflammatory treatment for asthma: inhaled steroid or leukotriene antagonist?
Source: Eur Respir J 2002; 20: Suppl. 38, 93s
Year: 2002

An oral selective M3 cholinergic receptor antagonist in COPD
Source: Eur Respir J 2006 Oct 01;28(4):772-780
Year: 2006



LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma
Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Year: 2013

A dual-acting muscarinic antagonist, ß2-agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

PF-3429281 – A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist in the anaesthetised dog model of bronchoconstriction
Source: Annual Congress 2010 - Bronchodilators in airways disease
Year: 2010

Efficacy and safety of abediterol, a long-acting beta2-adrenergic agonist (LABA); three phase II trials in asthma
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014

Anti-inflammatory effects of histamine H1-receptor antagonist and leukotriene CysLT1-receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids
Source: Eur Respir J 2004; 24: Suppl. 48, 221s
Year: 2004

Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017

Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Anti-inflammatory therapy COPD: fenspiride and(or) theophylline versus inhaled corticosteroids?
Source: Annual Congress 2007 - Treatment of COPD
Year: 2007